Edition:
United Kingdom

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

12.85USD
23 Oct 2018
Change (% chg)

$-0.49 (-3.67%)
Prev Close
$13.34
Open
$13.11
Day's High
$13.23
Day's Low
$12.64
Volume
170,760
Avg. Vol
116,695
52-wk High
$47.39
52-wk Low
$12.52

Latest Key Developments (Source: Significant Developments)

Five Prime Therapeutics Q2 Loss Per Share $0.99
Wednesday, 8 Aug 2018 

Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.99.Q2 EARNINGS PER SHARE VIEW $-1.29 -- THOMSON REUTERS I/B/E/S.ANTICIPATES INITIATING A PHASE 1 CLINICAL TRIAL OF FPT155 IN AUSTRALIA IN Q4 OF 2018.ESTIMATES ENDING 2018 WITH APPROXIMATELY $250 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.COLLABORATION AND LICENSE REVENUE FOR Q2 OF 2018 DECREASED BY $0.2 MILLION, OR 3%, TO $7.6 MILLION.  Full Article

Five Prime Therapeutics Announces Collaboration With Roche
Wednesday, 30 May 2018 

May 30 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS ANNOUNCES COLLABORATION WITH ROCHE TO DEVELOP COMPANION DIAGNOSTICS FOR TARGETED IMMUNO-ONCOLOGY INVESTIGATIONAL DRUG CANDIDATES.FIVE PRIME THERAPEUTICS INC - FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED..  Full Article

Five Prime Therapeutics Appointed Linda Rubinstein As Interim CFO
Tuesday, 17 Apr 2018 

April 17 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS INC - ON APRIL 13 APPOINTED LINDA RUBINSTEIN AS INTERIM CHIEF FINANCIAL OFFICER - SEC FILING.FIVE PRIME THERAPEUTICS INC - LINDA RUBINSTEIN, IS A PARTNER AT FLG PARTNERS, A CHIEF FINANCIAL OFFICER SERVICES AND BOARD ADVISORY CONSULTING FIRM.  Full Article

Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME.FIVE PRIME THERAPEUTICS INC - MILESTONE FOR ANTIBODY TARGETING TIM-3 TRIGGERS $5 MILLION PAYMENT TO FIVE PRIME.FIVE PRIME- BMS EXTENDS RESEARCH COLLABORATION TERM FOR DEVELOPMENT, COMMERCIALIZATION FOR THERAPEUTICS IN 3 IMMUNE CHECKPOINT PATHWAYS TO MARCH 2019.FIVE PRIME THERAPEUTICS INC - BRISTOL-MYERS SQUIBB WILL ALSO PROVIDE ADDITIONAL FUNDING TO FIVE PRIME FOR EXTENDED TERM OF RESEARCH COLLABORATION.  Full Article

Five Prime Therapeutics Submits Investigational New Drug Application For FPA150
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION FOR NOVEL B7-H4 ANTIBODY FPA150.FIVE PRIME THERAPEUTICS INC - ANTICIPATES INITIATING A PHASE 1 TRIAL OF FPA150 DURING FIRST HALF OF 2018.  Full Article

Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR FPA144 ANTI-FGFR2B ANTIBODY IN GREATER CHINA AND GLOBAL STRATEGIC DEVELOPMENT COLLABORATION.FIVE PRIME THERAPEUTICS - GRANTED ZAI LAB AN EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE FPA144 IN GREATER CHINA TERRITORY​.FIVE PRIME THERAPEUTICS INC - ‍ZAI LAB WILL BE RESPONSIBLE FOR CONDUCTING PHASE 3 FIGHT TRIAL IN GREATER CHINA​.  Full Article

Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Five Prime Therapeutics Inc :Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors.Bristol-Myers Squibb - ‍Preliminary results show safety profile of Cabiralizumab plus Opdivo was generally consistent with that of Opdivo monotherapy​.Bristol-Myers Squibb - ‍Early efficacy signal observed in heavily pretreated patients with advanced pancreatic cancer with microsatellite stable disease​.Bristol-Myers Squibb Co - ‍Bristol-Myers Squibb is launching a new study of Cabiralizumab plus Opdivo​.Bristol-Myers Squibb Co - ‍Data show for first time that combining an anti-csf-1 receptor antibody with Opdivo may help restore t cell function​.  Full Article

Five Prime posts Q3 loss of $1.54 per share
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Five Prime Therapeutics Inc :Five prime announces third quarter 2017 results and provides business update.Q3 loss per share $1.54.Q3 earnings per share view $-1.24 -- Thomson Reuters I/B/E/S.Five prime therapeutics inc - ‍collaboration revenue for q3 of 2017 increased by $1.6 million to $8.3 million​.  Full Article

Five Prime Therapeutics appoints Aron Knickerbocker as CEO
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Five Prime Therapeutics Inc :Five Prime Therapeutics announces appointment of Aron Knickerbocker as CEO effective January 1, 2018.Five Prime Therapeutics Inc - ‍ selected Aron Knickerbocker to succeed Lewis Williams, as president and CEO​.Five Prime Therapeutics Inc - ‍ Knickerbocker will maintain chief operating officer position until end of 2017​.  Full Article

BRIEF-Five Prime Therapeutics Announces Collaboration With Roche

* FIVE PRIME THERAPEUTICS ANNOUNCES COLLABORATION WITH ROCHE TO DEVELOP COMPANION DIAGNOSTICS FOR TARGETED IMMUNO-ONCOLOGY INVESTIGATIONAL DRUG CANDIDATES